Bio Saga Blog - A Chronicle of Life Sciences & Informatics

To design cells to spec, researchers still need better tools. MONDAY, JUNE 20, 2011 BY KATHERINE BOURZAC Last July , scientists created the first " synthetic cell ," an organism that's controlled by a chemically synthesized genome edited on a computer and stitched together in the lab. One year later, biologists at the  Fifth Annual Synthetic Biology  conference at Stanford University are still struggling to take the next step in the field. Holding them back are the vagaries of biology itself, and the expense and time needed to get from idea to engineered organism. While the creation of the synthetic cell, at the J. Craig Venter Institute , hints at a future in which synthetic biologists can redesign living cells to perform whatever tasks they dream up, that goal is still distant. Most research has focused on coaxing microbes to perform tasks that are similar to what they already do, such as transforming sugar into fuels using processes and materials that resemble the on

Persistent Systems Ltd (PSL) has signed an agreement to acquire Agilent Technologies' software marketing and development business unit based in Grenoble, France. The acquisition is expected to be final by August 1, after which the unit will be called Persistent Systems, France. Dr Anand Deshpande, Chairman and Managing Director, PSL said the acquisition will contribute to Persistent's thrust in the life sciences and healthcare markets and also give it a presence in Europe. Around 30 domain experts from Agilent will come on board once the transaction is completed and more may be added, he said. The Agilent business is now focused on supplying data acquisition and control software for scientific instruments to the life sciences, environmental, energy, applied research and other markets. Currently, PSL's Life Sciences business contributes 10-12 per cent to its topline and was worth $20 million in FY 2011. The team here includes over 40 domain experts and more than 500 softw